- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03374241
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211
April 27, 2018 updated by: Hanmi Pharmaceutical Company Limited
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Dose of HM15211 in Healthy Obese Subjects
Single ascending dose of HM15211 in healthy obese subjects.
Study Overview
Detailed Description
A First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics after single ascending dose of HM15211 in healthy obese subjects.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Chula Vista, California, United States, 91911
- Recruiting
- Hanmi Investigative Site
-
Contact:
- Hanmi Pharmaceuticals
- Phone Number: +82-2-410-9114
-
Contact:
- Phone Number: +82-2-410-9114
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Female subjects must be non-pregnant and non-lactating
Exclusion Criteria:
- Participation in an investigational study within 30 days prior to dosing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cohort 1
HM15211 or Placebo (single dose, subcutaneous injection)
|
Long-acting tri-agonist
|
EXPERIMENTAL: Cohort 2
HM15211 or Placebo (single dose, subcutaneous injection)
|
Long-acting tri-agonist
|
EXPERIMENTAL: Cohort 3
HM15211 or Placebo (single dose, subcutaneous injection)
|
Long-acting tri-agonist
|
EXPERIMENTAL: Cohort 4
HM15211 or Placebo (single dose, subcutaneous injection)
|
Long-acting tri-agonist
|
EXPERIMENTAL: Cohort 5
HM15211 or Placebo (single dose, subcutaneous injection)
|
Long-acting tri-agonist
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events
Time Frame: 1 month
|
An adverse event is any undesirable and unintended medical event occurring to a subject in a clinical study, whether or not related to the investigational products
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 4, 2018
Primary Completion (ANTICIPATED)
October 1, 2018
Study Completion (ANTICIPATED)
October 1, 2018
Study Registration Dates
First Submitted
December 12, 2017
First Submitted That Met QC Criteria
December 12, 2017
First Posted (ACTUAL)
December 15, 2017
Study Record Updates
Last Update Posted (ACTUAL)
May 1, 2018
Last Update Submitted That Met QC Criteria
April 27, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- HM-TRIA-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on HM15211 or Placebo
-
Hanmi Pharmaceutical Company LimitedCompleted
-
Hanmi Pharmaceutical Company LimitedRecruitingNASH - Nonalcoholic SteatohepatitisKorea, Republic of, United States
-
Samjin Pharmaceutical Co., Ltd.Completed
-
Hospital Ambroise Paré ParisCompletedLumbar RadiculopathyFrance
-
Arthrosi TherapeuticsCompletedHealthy VolunteersAustralia
-
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Recruiting
-
HK inno.N CorporationUnknownHealthyKorea, Republic of
-
Huabo Biopharm Co., Ltd.Completed
-
Creabilis SALCG BioscienceCompleted
-
Intron Biotechnology, Inc.CompletedAcute Radiation SyndromeKorea, Republic of